Molecular Formula | C12H10ClNO4 |
Molar Mass | 267.67 |
Density | 1.490±0.06 g/cm3(Predicted) |
Melting Point | 159.1-160.1 °C |
Boling Point | 408.7±45.0 °C(Predicted) |
pKa | 4.50±1.00(Predicted) |
Storage Condition | 2-8℃ |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.736 ml | 18.68 ml | 37.36 ml |
5 mM | 0.747 ml | 3.736 ml | 7.472 ml |
10 mM | 0.374 ml | 1.868 ml | 3.736 ml |
5 mM | 0.075 ml | 0.374 ml | 0.747 ml |
Overview | laquinimod is a new immunomodulator developed by Teva that requires only once-daily oral administration. It is used for the treatment of active relapsing well-transformed multiple sclerosis. Laquinimod has obvious advantages over existing drugs, has an anti-inflammatory effect and neuroprotective effect. The intermediate laquinimod can be used for the preparation of laquinimod. |